NRAS G13D
Clinical trials for NRAS G13D explained in plain language.
Never miss a new study
Get alerted when new NRAS G13D trials appear
Sign up with your email to follow new studies for NRAS G13D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug hopes to shrink NRAS-Driven cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…
Matched conditions: NRAS G13D
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: NRAS G13D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC